Evidence map›Paper›PMID 34268520›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccine.

Lela Kardava, Nicholas Rachmaninoff, William W Lau, Clarisa M Buckner, Krittin Trihemasava, Felipe Lopes de Assis, Wei Wang, Xiaozhen Zhang, Yimeng Wang, Chi-I Chiang and 17 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 1 country.

Lela Kardava *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Nicholas Rachmaninoff *Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
William W Lau *Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
Clarisa M BucknerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Krittin TrihemasavaLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Felipe Lopes de AssisLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Wei WangLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Xiaozhen ZhangLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Yimeng WangInstitute for Bioscience and Biotechnology Research, Rockville, MD, USA.
Chi-I ChiangInstitute for Bioscience and Biotechnology Research, Rockville, MD, USA.
Sandeep NarpalaVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Robert RegerCellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, USA.
Genevieve E McCormackLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Catherine A SeamonCritical Care Medicine Department, National Institutes of Health Clinical Center, NIH, Bethesda, MD, USA.
Richard W ChildsCellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, USA.
Anthony F SuffrediniCritical Care Medicine Department, National Institutes of Health Clinical Center, NIH, Bethesda, MD, USA.
Jeffrey R StrichCritical Care Medicine Department, National Institutes of Health Clinical Center, NIH, Bethesda, MD, USA.
Daniel S ChertowLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Richard T DaveyLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Michael C SnellerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Sarah O'ConnellVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Yuxing LiInstitute for Bioscience and Biotechnology Research, Rockville, MD, USA.
Adrian McDermottVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Tae-Wook ChunLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Anthony S Fauci *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
John S Tsang *Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.
Susan Moir *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
National Institutes of Health · USInstitute for Bioscience and Biotechnology ResearchNational Heart Lung and Blood Institute · USNational Institutes of Health Clinical Center · USUnited States Public Health Service Commissioned Officers Association · USUniversity of Maryland, Baltimore · US

Funding

Allogeneic Immunotherapy for cancer and nonmalignant hematological disordersZIAHL002345 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHILDS, RICHARD · 2009 to 2025
$53.3M
Influenza and Emerging Infectious DiseasesZIAAI000984 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DAVEY, RICHARD · 2009 to 2025
$44.1M
Role of Viral Reservoirs in the Pathogenesis of HIV DiseaseZIAAI000851 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHUN, TAE-WOOK · 2009 to 2025
$29.3M
Role of B Lymphocytes In HIV Infection And PathogenesisZIAAI000825 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOIR, SUSAN · 2009 to 2025
$24.5M
Integrative analysis and modeling of human immune responses and pathologiesZIAAI001152 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI TSANG, JOHN · 2011 to 2022
$14.1M
High-resolution definition of B cell responses to HIV Env for immunogen designR01AI102766 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI LI, YUXING · 2013 to 2024
$6.6M
Next Generation Broadly Neutralizing Antibodies to Clear HIV-1 ReservoirR01AI136756 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LI, QINGSHENG, LI, YUXING · 2019 to 2023
$3.9M
A Phase II Study Evaluating Fostamatinib for Hospitalized Adults with COVID-19.ZIAHL006250 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHILDS, RICHARD · 2020 to 2023
$2.4M
Immunologic Studies Associated with COVID-19 ZIAAI001325 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOIR, SUSAN · 2020 to 2025
$1.3M
Systems Immunology of COVID-19ZIAAI001266 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI TSANG, JOHN · 2020 to 2022
$1.2M
Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic PersonsZIACL090062 · CLC · CLINICAL CENTER · PI SUFFREDINI, ANTHONY F. · 2020 to 2025
$0k
NIAID NIH HHS R01 AI102766NIAID NIH HHS R01 AI136756
6 · The paper itself

Abstract

SARS-CoV-2 mRNA vaccines are highly effective, although weak antibody responses are seen in some individuals with correlates of immunity that remain poorly understood. Here we longitudinally dissected antibody, plasmablast, and memory B cell (MBC) responses to the two-dose Moderna mRNA vaccine in SARS-CoV-2-uninfected adults. Robust, coordinated IgA and IgG antibody responses were preceded by bursts of spike-specific plasmablasts after both doses, but earlier and more intensely after dose two. Distinct antigen-specific MBC populations also emerged post-vaccination with varying kinetics. We identified antigen non-specific pre-vaccination MBC and post-vaccination plasmablasts after dose one and their spike-specific counterparts early after dose two that correlated with subsequent antibody levels. These baseline and response signatures can thus provide early indicators of serological efficacy and explain response variability in the population.

Identifiers

PMID34268520
PMCPMC8282109
OpenAlexW3181312010

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.